Torsten Haferlach

BMW (Germany) — Germany

Medicine · Health Sciences

118h-index60.6kcitations2.0kworks3.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(1103), Myeloproliferative Neoplasms: Diagnosis and Treatment(372), Chronic Myeloid Leukemia Treatments(325), Chronic Lymphocytic Leukemia Research(289), Acute Lymphoblastic Leukemia research(218)

Publications1.7k total

Solving Riddles Through Sequencing (SIRIUS): unlocking hematologic diagnoses by whole genome and transcriptome sequencing
Leukemia·2025Open Access
Image-based explainable artificial intelligence accurately identifies myelodysplastic neoplasms beyond conventional signs of dysplasia
npj Precision Oncology·2025· 1 citedOpen Access
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice
Science Translational Medicine·2025
A tumor-selective mRNA system enables precision cancer treatment
Molecular Therapy·2025Open Access
EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group
Blood·2025Open Access
Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database
Blood·2025Open Access
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome
Blood·2025
Bi-allelic TET2 alterations are frequently found in NPM1 mutated AML and constitute a distinct subgroup with unfavorable prognosis
Blood·2025Open Access
Non-invasive MDS diagnostic algorithm can also identify pre-MDS and distinguishes normal controls from MDS/pre-MDS patients without bone marrow examination
Blood·2025Open Access
Additional genetic targets are present in the majority of AML patients with NPM1, KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors
Blood·2025Open Access
MPN with multiple driver clones show distinct patterns of therapy response and progression - “MPN double driver”
Blood·2025Open Access
Safe: A multimodal, scalable and clinically-oriented comprehensive framework for synthetic data validation in hematology
Blood·2025Open Access
The PDI-ATF6-axis as a novel treatment target in CSF3R driven chronic neutrophilic leukemia (CNL)
Blood·2025
Artificial intelligence‑driven virtual tumor board enhances precision care in myelodysplastic syndromes (MDS)
Blood·2025
The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms
Blood·2025Open Access
Refining the prognostic hierarchy of TP53 multihit alterations and isolated deletion of chromosome 5q in myelodysplastic syndromes
Blood·2025· 1 citedOpen Access
MDS without clonal marker: When depth outperforms breadth
Blood·2025Open Access
17p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease
Blood·2025Open Access
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database
Blood·2025Open Access
Independent, international validation of the unsupervised harmony classification of Acute Myeloid Leukemia
Blood·2025
page 1 of 86Next →

Frequent Co-authors

Susanne Schnittger(25), Wolfgang Kern(24), Claudia Haferlach(18), Claudia Schoch(13), Wolfgang Hiddemann(13), Alexander Kohlmann(9), Seishi Ogawa(8), Kenichi Yoshida(7), Manja Meggendorfer(7), Masashi Sanada(6), Yuichi Shiraishi(6), Yasunobu Nagata(6), Satoru Miyano(6), Tamara Alpermann(6), Thomas Büchner(6), Frank Dicker(6), Nicholas C.P. Cross(5), H. Phillip Koeffler(5), Kenichi Chiba(5), Hiroko Tanaka(5)